Shire Confident Of Vyvanse Approval, Despite Second ‘Approvable’ Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Adderall XR follow-on still slated for Q2 2007 launch.
You may also be interested in...
Shire Specialty Pharmaceuticals President Mike Cola: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Shire’s head of ADHD, renal and GI products talks about upcoming launches, a sales force reconfiguration and licensing and acquisitions.
Shire Specialty Pharmaceuticals President Mike Cola: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Shire’s head of ADHD, renal and GI products talks about upcoming launches, a sales force reconfiguration and licensing and acquisitions.
Shire Anticipates Vyvanse Approval In “Next Month Or Two”
The firm is considering a marketing partner and aims to replace its ADHD treatment Adderall XR with Vyvanse.